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Edited by Michael R. BubbAbstract b-Dystroglycan is the central member of a trans-
membrane protein complex of the skeletal muscle plasma
membrane. Since it was not detected in dystrophin-deﬁcient
skeletal muscles, a disruption of the complex was thought to be
involved in the dystrophic process. We report here that b-
dystroglycan is actually present at normal levels in mdx mouse
muscle plasma membrane: treatment with cholate detergent is
able to reveal its presence by SDS–PAGE and immunoblotting.
This result shows that, in dystrophin-deﬁcient muscles, b-
dystroglycan is indeed targeted to the plasma membrane but
remains inaccessible to classical solubilizing treatments and to
antibodies used for immunolocalization.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Muscular dystrophy; Dystrophin–glycoprotein
complex; mdx mouse; b-Dystroglycan; Dystrophin-deﬁcient
muscle1. Introduction
Duchenne muscular dystrophy (DMD) [1] and mdx mouse
dystrophy [2] result from X-linked genetic defects leading to a
lack of dystrophin. Dystrophin [3] is located on the cytoplas-
mic side of the skeletal muscle plasma membrane [4] and is
involved in the dystrophin–glycoprotein complex (DGC). The
DGC consists of the integral membrane proteins b-dystrogly-
can, the sarcoglycans and sarcospan, along with the extracel-
lular protein a-dystroglycan as well as the cytoplasmic proteins
dystrophin and the syntrophins (for a review, see [5]). The
C-terminal domain of dystrophin binds to the intracellular
domain of b-dystroglycan [6,7], which in turn binds to a-dys-
troglycan, thus establishing a transmembrane link between the
extracellular matrix and the cytoskeleton network. F-actin
[8,9] and membrane phospholipids [10] are other known
partners of dystrophin domains.
Experimental studies have failed to detect DGC in the dys-
trophin-deﬁcient skeletal muscles of DMD patients [11–13]
and mdx mouse [14]. Hence, this complex was assumed to be* Corresponding author. Fax: +33-223-234-606.
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doi:10.1016/j.febslet.2004.07.032disrupted in the absence of dystrophin, and appeared to be
involved in the development of the disease.
However, the level of expression of mRNA encoding for the
dystroglycans is similar in dystrophin-deﬁcient and normal
mouse and human muscle [12,15]. Therefore, two main hy-
potheses may be advanced. The DGC proteins could be hy-
drolysed immediately after translation and are not transported
to the sarcolemma, or the DGC proteins could be well targeted
onto the sarcolemma but are not detectable due to a secondary
modiﬁcation.
The present work shows for the ﬁrst time that b-dystrogly-
can is present as an insoluble protein in dystrophin-deﬁcient
muscle plasma membrane.2. Materials and methods
2.1. Animals
Normal (C57BL/10Sc/Scn) and mdx (C57BL/10Sc/Scn/mdx) mice
were bred at the Ecole Nationale Veterinaire in Nantes.
2.2. Antibodies
For immunoblotting, we used mouse monoclonal antibodies: anti-
dystrophin (NCL-DYS2), anti-b-dystroglycan (NCL-b DG) from
Novocastra Laboratories (Tebu France, Le Peray en Yvelines,
France); mouse anti-calsequestrin (VIIID12) was supplied by Aﬃnity
Bioreagents (Coger SA, Paris, France); anti-Utrophin (MANCHO-3)
was kindly provided by Prof. G. Morris (MRCI Biochemistry Group,
Wrexham, UK); anti-Golgi 58K protein (58K-9) was from Sigma.
Alkaline phosphatase conjugated donkey anti-mouse secondary anti-
body was from Chemicon International (Euromedex, Mundolsheim,
France).
2.3. Isolation of crude surface membranes
For each preparation, normal and mdx mice (8–24 weeks old) were
euthanized by i.p. pentobarbital injection, and whole hind-leg muscle
samples were taken.
Crude surface membranes were isolated at 4 C as described in detail
elsewhere [4,16] and as shown in Fig. 1A.
2.4. SDS–PAGE and immunoblotting
SDS–PAGE was performed on 8% or 10% polyacrylamide gel fol-
lowing classical procedures of Laemmli [17] and Towbin et al. [18]
using secondary antibody coupled to alkaline phosphatase. When
quantiﬁcation of a speciﬁc protein was required, the immunoblots were
developed using a ﬂuorescent substrate for alkaline phosphatase (ECF,
Amersham) and the ﬂuorescence emission was directly measured by
ﬂuorescence scanning equipment (Storm instrument, Amersham, and
Image-Quant 5.2).ation of European Biochemical Societies.
Fig. 1. Skeletal muscle fractionation from normal and mdx mouse. (A) Puriﬁcation protocol: buﬀer A is 20 mM sodium pyrophosphate, 20 mM
sodium phosphate, 1 mM MgCl2, 0.3 M sucrose, 0.5 mM EDTA, at pH 7.0 with protease inhibitors; buﬀer B is 0.303 M sucrose, 20 mM Tris–
maleate, at pH 7.0. (B) SDS–PAGE and immunoblotting of several proteins performed on the successive fractions obtained along with the frac-
tionation procedure of (A).
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3.1. Muscle fractionation
KCl-washed microsomes (KCl-Ms) and crude surface
membranes (CSM) were obtained from skeletal muscle
through a well established procedure (Fig. 1A). SDS–PAGE
and immunoblotting of the Golgi 58K protein showed that
Golgi membranes were highly enriched in supernatant S2 and
that KCl-Ms and CSM were largely devoid of these constitu-
ents. By contrast, P2, KCl-Ms and CSM were largely enriched
in dystrophin from normal mouse muscle and in utrophin
when derived from mdx mouse muscle (Fig. 1B). In parallel,
calsequestrin, a marker of the SR, was highly enriched in P1,
P2, KCl-Ms and the ﬁnal pellet but decreased markedly in S3Table 1
Quantiﬁcation of several markers in the fractions obtained from normal and
Normal mouse
S1 KCl-Ms CSM F
Total protein lg/g of muscle 20 1
ACHase IU/mg protein (n ¼ 6) 5 1 8 4 25 1 6
50N IU/mg protein (n ¼ 3) 2 4 15.5 2
Calsequestrin (%) 6 1 100 6 0 2
b-DG 43 (%) 100 430 8 4
b-DG 30 (%) 119
Total b-DG (%) 100 440
The fractions are those shown in Fig. 1A.
Calsequestrin, b-DG 43 and 30 kDa levels are obtained from the ﬂuorescen
reference value is assigned arbitrarily to KCl-Ms. MeansS.D. are done.and CSM (Fig. 1B). CSM was also enriched in the two plasma
membrane markers, acetylcholinesterase and 50nucleotidase,
compared with S1, KCl-Ms and the ﬁnal pellet (Table 1).
Therefore, KCl-Ms appeared to be a mixture of SR and
plasma membranes while CSM appeared largely free of SR
membranes and enriched in plasma membranes.
3.2. b-Dystroglycan in CSM and KCl-Ms
SDS–PAGE and immunoblotting revealed a faint label for
b-DG migrating at 43 kDa in normal muscle P2, the label
being strongly enhanced in KCl-Ms and CSM (Fig. 1B). In
mdx mouse muscle, no label appeared in any of the fractions
except for CSM where strong labels appeared in two bands
migrating at 43 and 30 kDa.mdx mouse muscle by the skeletal muscle fractionation procedure
mdx Mouse
inal pellet S1 KCl-Ms CSM Final pellet
20 1
 0 4.5 2 105 24 10 6 0
3 4 15 2
71 13 5 0 101 2 5 1 263 13
 1 132 90
282 100
414
ce intensity of the bands in the Western blots in Fig. 2 and the 100%
Fig. 3. b-DG can be revealed by cholate treatment of KCl-Ms from
mdx mouse muscles. A 2% sodium cholate treatment for 2 h, followed
by overnight 2% SDS dialysis for half of the fraction. Then, SDS–
PAGE and immunoblotting for b-DG were performed on KCl-Ms
from normal and mdx mouse muscle. Fluorescence was quantiﬁed in
three identical blots and the levels normalized using a level of 100 for
the non-treated KCl-Ms from normal mouse muscle: (1) normal
mouse, no treatment; (2) mdx mouse, no treatment; (3) normal mouse,
2% cholate; (4) mdx mouse, 2% cholate; (5) normal mouse, 2% cholate
and SDS dialysis; (6) mdx mouse, 2% cholate and SDS dialysis.
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70% of the total ﬂuorescence observed for b-DG in CSM from
mdx muscle, while this band was absent from the normal
muscle CSM (Fig. 2 and Table 1). The total ﬂuorescence levels
of b-DG of CSM were similar in mdx and normal mouse
muscle. Calsequestrin was used as a counter marker and
showed opposite expressions in these fractions (Fig. 2 and
Table 1).
3.3. b-DG revealed by detergent treatment of KCl-Ms
Considering the presence of b-DG in CSM from mdx mouse
muscle and its non-visibility in corresponding KCl-Ms, we
hypothesized that b-DG is indeed present in KCl-Ms but not
solubilized by SDS present in the loading buﬀer for SDS–
PAGE. We used several detergents in an attempt to solubilize
b-DG from these KCl-Ms. A 2% cholate treatment for 2 h at
room temperature yielded a strong label for b-DG in mdx and
in normal KCl-Ms (Fig. 3). Only one band migrating at 43
kDa was observed in both muscle fractions. The intensity of
the band was similar in mdx and normal mouse muscle.
We therefore considered that the appearance of the b-DG 30
kDa band in mdx CSM could be due to proteolysis occurring
during the long duration of the sucrose density gradient cen-
trifugation. To test this hypothesis, KCl-Ms from normal and
mdx mouse muscle were incubated overnight at 4 C. This
treatment failed to reveal b-DG in KCl-Ms (not shown);
however, a 2% cholate treatment was able to reveal one band
migrating at 43 kDa (not shown) as observed in Fig. 3. In
addition, assuming that b-DG insolubility in mdx mouse could
be due to intermolecular disulﬁde bridges, SDS–PAGE was
performed under non-reducing conditions. The immunoblots
were similar under both reducing and non-reducing conditions
for the three fractions S1, KCl-Ms and CSM, with or without
cholate treatment (results not shown).Fig. 2. b-DG is absent in the KCl-Ms from mdx mouse muscle but
present in CSM of normal as well as mdx mouse muscle. Immunoblots
were performed for b-DG and calsequestrin on the four fractions: S1,
KCl-Ms, CSM and the ﬁnal pellet obtained from normal and mdx
mouse muscle. Fluorescence was quantiﬁed in three identical blots and
reported in Table 1. Ponceau red staining is shown at the bottom.4. Discussion
In this paper, we show for the ﬁrst time the presence of a
pool of SDS-insoluble b-DG in microsomes from dystrophin-
deﬁcient mdx mouse muscle. Furthermore, we describe the
presence of a pool of b-DG in crude surface membranes from
normal and mdx mouse.
The method of plasma membrane puriﬁcation used in our
work was derived from the work of Ohlendieck et al. [7]. We
ﬁrst checked the yield in marker proteins for the fractions and
showed that in normal as well as mdx mouse muscle: (i) KCl-
Ms were composed of SR and plasma membranes devoid of
Golgi membranes, (ii) CSM fractions were reasonably free of
SR and enriched in plasma membrane markers. Therefore, the
dystrophic process does not seem to alter the composition in
marker proteins of mdx mouse fractions compared to normal
mouse. However, we found that dystrophin was absent and
utrophin overexpressed in mdx mouse preparations, so we
could then quantitatively compare further data obtained in
normal and mdx mouse muscle.
b-DG is a glycoprotein of the plasma membrane that can
be detected in KCl-Ms using SDS–PAGE and immunoblot-
ting as a unique band migrating at 43 kDa [5,7]. Accordingly,
we were able to reveal b-DG in KCl-Ms of normal mouse.
Using the same method, b-DG has been shown to be highly
depleted or absent in KCl-Ms from mdx mouse [11,14], as
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our ﬁrst results were in agreement with the cited studies, we
then showed that b-DG can be detected in KCl-Ms from mdx
mouse after a cholate detergent treatment. The quantitative
results indicated that the pools of b-DG were similar in both
mdx and normal mouse muscle. Although KCl-Ms were lar-
gely contaminated by SR but devoid of Golgi membranes,
KCl-Ms from both mdx and normal muscle have similar
protein proﬁles and are similarly enriched in plasma mem-
brane markers. Therefore, as Golgi membranes are absent
from these fractions and b-DG has never been shown to be
associated with SR membranes [4,21], we conclude that b-DG
is indeed targeted onto the plasma membrane of dystrophin-
deﬁcient mdx mouse muscle.
It is not known why cholate is able to reveal b-DG from this
muscle while SDS does not. At present, we have no data to
explain this result. It could be related to the fact that SDS has
a poorer phospholipid solubilization action in contrast to
cholate [22]. To modify the protein structure, SDS needs to
interact with accessible charged residues of a protein via its
hydrophilic charged domain, which thus produces solubiliza-
tion and unfolding. This is not the case for certain membrane
proteins such as bacteriorhodopsin [22], which are embedded
in the phospholipid bilayer and which need long detergent
interaction to achieve solubilization. Therefore, we may hy-
pothesize that b-DG of mdx mouse muscle plasma membrane
is not accessible to SDS. Moreover, the non-solubility of b-DG
in SDS could not be due to an aggregation of the molecules by
intermolecular disulﬁde bridges because SDS–PAGE under
non-reducing conditions does not modify the migration proﬁle
of the b-DG.
The only additional data about the non-solubility of mdx
KCL-Ms b-DG in SDS are from the CSM obtained by sucrose
density gradient centrifugation of KCl-Ms. SDS–PAGE and
immunoblotting reveal the presence of b-DG in the CSM
fraction from both mdx and normal mouse muscle. However,
in mdx mouse CSM, b-DG appears as two bands migrating at
43 and 30 kDa, while in normal CSM, only one band at 43
kDa could be observed. The antibody used here recognizes the
b-DG intracellular domain. A cleavage product migrating at
30 kDa has already been observed in ischemic heart [23] and in
cancer cells [24], being due to the release of the b-DG extra-
cellular domain that interacts with the extracellular a-DG by
activation of metalloproteinases. In dystrophic muscle, this
cleavage could arise from the proteases known to be highly
activated in these muscles.
Our results on b-DG obtained with mdx mouse muscle
preparations appear quite surprising considering that b-DG
could not be revealed in these preparations by the usual SDS–
PAGE method in agreement with numerous previous studies.
Instead, we obtained the following results:
(i) b-DG can be revealed in KCl-Ms using detergent treat-
ment, indicating that it is SDS-insoluble in KCl-Ms;
(ii) b-DG is detected in CSM by routine methods, indicating
that it is SDS-soluble in CSM;
(iii) b-DG found in CSM consists of 70% of the cleaved prod-
uct and 30% of the native protein;
(iv) there are similar levels of b-DG 43 kDa in mdx and nor-
mal mouse muscle KCl-Ms after cholate treatment;
(v) b-DG 30 and 43 kDa of mdx mouse muscle CSM show
similar levels to b-DG 43 kDa in CSM from normal
mouse muscle.Therefore, it appears that proteolysis of b-DG occurs
speciﬁcally in the KCl-Ms of mdx mouse muscle during the
sucrose density gradient centrifugation, thus allowing SDS-
solubilization of b-DG in the corresponding CSM. This
proteolysis does not occur without the centrifugation since the
overnight incubation is not followed by b-DG labelling of mdx
KCl-Ms and a cholate treatment reveals only the b-DG 43
kDa. The striking feature is that such a cleavage does not
occur in normal muscle.
Our results are in line with the fact that immunoﬂuorescence
analysis fails to detect b-DG in mdx mouse muscle. While it
appears that b-DG is present, its intracellular domain is not
accessible to the antibody, and this prevents its labelling.
Therefore, in mdx mouse muscle plasma membrane, the intra-
and extra-cellular domains of b-DG become inaccessible to the
SDS of the loading buﬀer for SDS–PAGE analysis as well as to
antibodies used for immunoﬂuorescence analysis.
We have no explanation for the real diﬀerence in solubility
of b-DG between normal and mdx mouse muscles. Neverthe-
less, we are able to reconcile the occurrence of normal b-DG
mRNA levels in mdx compared to normal mouse muscle
[12,15] with the observation that b-DG could not be revealed
by either SDS–PAGE or the usual immunoﬂuorescence
methods due to an inaccessibility of its intra- and extra-cellular
domains. Therefore, the major conclusion from our data is
that b-DG is targeted onto the plasma membrane in similar
amounts in both normal and mdx mouse muscle, but that, in
mdx mouse muscle, b-DG is insoluble in SDS and soluble in
cholate. Research is in progress in order to ascertain whether
the same results can be obtained with the other members of the
DGC and with human DMD skeletal muscle.
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